TREATMENT OF REFRACTORY ACUTE-LEUKEMIA WITH ACLACINOMYCIN-A

Publisher Website
Google Scholar
Abstract
Twelve patients with refractory acute leukemia (7 patients with acute myelocytic leukemia and 5 with acute lymphocytic leukemia) were treated with a new anthracycline anthracycline antibiotic, aclacinomycin-A (ACM). ACM was administrated by i.v. drip infusion at a dose of 20 mg/day for 7 or 14 days; this was repeated after at least 7 days. Four of 12 patients (33.3%) achieved a compete remission (3 of 7 acute myelocytic leukemia, 42.8%; 1 of 5 acute lymphocytic leukemia, 20.0%). The days required for achieving the complete remission ranged at 23-78 days (median: 61), the total doses of ACM used, 180-500 mg (median: 310) and the durations of complete remission 11-28+ wk (median: 21). The untoward effects on digestive organs, such as nausea, vomiting and anorexia, and hematological toxicities were frequent; they were controlled by supportive treatment. Alopecia was not observed. Arrythmia was recognized in 1 patient at the initiation of ACM infusion with complete remission without withdrawal of ACM. ACM could be is a potentially effective anthracycline antibiotic in the clinical management of acute leukemia.

This publication has 1 reference indexed in Scilit: